A Randomized, Placebo-controlled, Parallel Group, Patient-blind, Phase I Study Assessing the Safety and Exploring the Immunogenicity/Therapeutic Activity of AFFITOPE PD01A and PD03A in Patients With Early Multiple System Atrophy

Trial Profile

A Randomized, Placebo-controlled, Parallel Group, Patient-blind, Phase I Study Assessing the Safety and Exploring the Immunogenicity/Therapeutic Activity of AFFITOPE PD01A and PD03A in Patients With Early Multiple System Atrophy

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Jun 2017

At a glance

  • Drugs Affitope PD01 (Primary) ; Affitope PD03 (Primary)
  • Indications Multiple system atrophy
  • Focus Adverse reactions
  • Sponsors AFFiRiS
  • Most Recent Events

    • 07 Jun 2017 According to an AFFiRiS media release, this study is part of SYMPATH research project.
    • 02 Jun 2017 Status changed from active, no longer recruiting to completed.
    • 07 Sep 2016 According to an AFFiRiS media release, results of this study is expected in Q4 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top